Guardant Health’s Shield colorectal cancer screening test gained a coverage tailwind after UnitedHealthcare announced it will cover Shield as a first-line screening assay for average-risk adults in defined age ranges. The payer’s decision also requires follow-up colonoscopy after abnormal results, aligning coverage with FDA labeling. Analysts characterized the move as precedent-setting, potentially accelerating Guardant’s access strategy and volume growth tied to broader contracting and guideline-aligned screening adoption.